01:18 , Dec 13, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived liver and bile duct cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by treating patient tumor samples with collagenase and deoxyribonuclease I (DNASE1)...
21:21 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Alidornase alfa: Interim Ph II data

Interim data from an open-label, Israeli Phase II trial in 13 evaluable CF patients previously treated with Pulmozyme dornase alfa showed that once-daily 2.5 mg inhaled alidornase alfa for 28 days led to a 4.1...
01:45 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

AIR DNase: Completed Ph II enrollment

Protalix completed enrollment of 15 patients switching over from Pulmozyme dornase alfa in an open-label, Israeli Phase II trial evaluating 2.5 mg inhaled AIR DNase once daily for 28 days. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting neutrophil extracellular trap s (NETs) with DNASE1 or other agents could help treat metastatic breast cancer. In primary tumor samples from 20 patients...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

AIR DNase: Phase II started

Protalix began an open-label, Israeli Phase II trial to evaluate 2.5 mg inhaled AIR DNase once daily for 28 days in 15 patients switching over from Pulmozyme dornase alfa. Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX),...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Deoxyribonuclease I like 3 (DNASE1L3)

Autoimmune disease INDICATION: Lupus Patient sample and mouse studies suggest DNASE1L3 could help treat lupus caused by mutations in the gene. In vitro, sera from DNASE1L3-deficient mice and lupus patients digested less DNA from apoptotic...
07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Guiding the way

George Church's Harvard Medical School lab is addressing head-on one of the biggest limitations of CRISPR-based gene editing: Until the tech has been proven to cut only where and when needed, it won't make the...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

PulmoXen: Phase I data

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the trial, plans to start...
07:00 , Jun 5, 2000 |  BC Week In Review  |  Company News

Universitatsklinikum Essen other research news

Essen researchers and colleagues published in Nature Genetics that mice deficient in DNase l develop symptoms of the autoimmune disease systemic lupus erythematosus (SLE), including anti-nuclear antibodies and glomerulonephritis. Also, DNase 1 activity was found...